202 related articles for article (PubMed ID: 11695560)
21. Panel discussion on the application of alternative models to cancer risk assessment.
Pettit SD
Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
[TBL] [Abstract][Full Text] [Related]
22. Alternative models for carcinogenicity testing.
Cohen SM; Robinson D; MacDonald J
Toxicol Sci; 2001 Nov; 64(1):14-9. PubMed ID: 11606797
[TBL] [Abstract][Full Text] [Related]
23. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice.
Mahler JF; Flagler ND; Malarkey DE; Mann PC; Haseman JK; Eastin W
Toxicol Pathol; 1998; 26(4):501-11. PubMed ID: 9715509
[TBL] [Abstract][Full Text] [Related]
24. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
25. Criteria for the evaluation of studies in transgenic models.
Popp JA
Toxicol Pathol; 2001; 29 Suppl():20-3. PubMed ID: 11695558
[TBL] [Abstract][Full Text] [Related]
26. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
Robinson DE; MacDonald JS
Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
[TBL] [Abstract][Full Text] [Related]
27. The in vivo rodent test systems for assessment of carcinogenic potential.
van der Laan JW; Spindler P
Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
[TBL] [Abstract][Full Text] [Related]
28. Heterozygous p53-deficient mice are not susceptible to 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) carcinogenicity.
Park CB; Kim DJ; Uehara N; Takasuka N; Hiroyasu BT; Tsuda H
Cancer Lett; 1999 May; 139(2):177-82. PubMed ID: 10395176
[TBL] [Abstract][Full Text] [Related]
29. Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa-/-p53+/- mice upon exposure to benzo[a]pyrene.
van Kesteren PC; Zwart PE; Pennings JL; Gottschalk WH; Kleinjans JC; van Delft JH; van Steeg H; Luijten M
Toxicol Sci; 2011 Sep; 123(1):123-32. PubMed ID: 21715664
[TBL] [Abstract][Full Text] [Related]
30. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
Takaoka M; Sehata S; Maejima T; Imai T; Torii M; Satoh H; Toyosawa K; Tanakamaru ZY; Adachi T; Hisada S; Ueda M; Ogasawara H; Matsumoto M; Kobayashi K; Mutai M; Usui T
Toxicol Pathol; 2003; 31(2):191-9. PubMed ID: 12696579
[TBL] [Abstract][Full Text] [Related]
31. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice.
Hulla JE; French JE; Dunnick JK
Carcinogenesis; 2001 Jan; 22(1):89-98. PubMed ID: 11159746
[TBL] [Abstract][Full Text] [Related]
32. Expectations for transgenic rodent cancer bioassay models.
Ashby J
Toxicol Pathol; 2001; 29 Suppl():177-82. PubMed ID: 11695555
[TBL] [Abstract][Full Text] [Related]
33. The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model.
Tennant RW; Stasiewicz S; Eastin WC; Mennear JH; Spalding JW
Toxicol Pathol; 2001; 29 Suppl():51-9. PubMed ID: 11695562
[TBL] [Abstract][Full Text] [Related]
34. Toxicology and carcinogenesis studies of p-nitrotoluene (CAS no. 99-99-0) in F344/N rats and B6C3F(1) mice (feed studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2002 May; (498):1-277. PubMed ID: 12118261
[TBL] [Abstract][Full Text] [Related]
35. Lack of susceptibility of heterozygous p53-knockout CBA and CIEA mice to phenolphthalein in a 6-month carcinogenicity study.
Okamura M; Kashida Y; Watanabe T; Yasuhara K; Onodera H; Hirose M; Usui T; Tamaoki N; Mitsumori K
Toxicology; 2003 Mar; 185(1-2):17-22. PubMed ID: 12505441
[TBL] [Abstract][Full Text] [Related]
36. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
MacDonald J; French JE; Gerson RJ; Goodman J; Inoue T; Jacobs A; Kasper P; Keller D; Lavin A; Long G; McCullough B; Sistare FD; Storer R; van der Laan JW
Toxicol Sci; 2004 Feb; 77(2):188-94. PubMed ID: 14657512
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the carcinogenic potential of clofibrate in the p53+/- mouse.
Torrey CE; Campbell JA; Hoivik DJ; Miller RT; Allen JS; Mann PC; Selinger K; Rickert D; Savina PM; Santostefano MJ
Int J Toxicol; 2005; 24(5):289-99. PubMed ID: 16257849
[TBL] [Abstract][Full Text] [Related]
38. Carcinogenicity of dimethylarsinic acid in p53 heterozygous knockout and wild-type C57BL/6J mice.
Salim EI; Wanibuchi H; Morimura K; Wei M; Mitsuhashi M; Yoshida K; Endo G; Fukushima S
Carcinogenesis; 2003 Feb; 24(2):335-42. PubMed ID: 12584185
[TBL] [Abstract][Full Text] [Related]
39. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
[TBL] [Abstract][Full Text] [Related]
40. Phenobarbital does not promote hepatic tumorigenesis in a twenty-six-week bioassay in p53 heterozygous mice.
Sagartz JE; Curtiss SW; Bunch RT; Davila JC; Morris DL; Alden CL
Toxicol Pathol; 1998; 26(4):492-500. PubMed ID: 9715508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
